24-HN-41-RMI (ASP-1929-381): A Phase 3 Multicenter, Randomized, Double-arm, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With

Grants and Contracts Details

StatusActive
Effective start/end date12/5/2412/5/26

Funding

  • Rakuten Medical Incorporated: $2.00